Xi'an Oripharm Technology Co.,Ltd

“Dedicated to providing you with the best product solutions!”

About Us
Factory Tour
Quality Control
Contact Us
Request A Quote
Home ProductsActive Pharmaceutical Ingredient

99% Min Assay Raloxifene HCL Evista Estrogen Receptor Antagonist CAS 82640-04-8

99% Min Assay Raloxifene HCL Evista Estrogen Receptor Antagonist CAS 82640-04-8

99% Min Assay Raloxifene HCL Evista Estrogen Receptor Antagonist CAS 82640-04-8

Product Details:

Place of Origin: China
Brand Name: ORIPHARM
Certification: KOSHER/ISO9001/SGS
Model Number: XALY

Payment & Shipping Terms:

Minimum Order Quantity: 10g
Packaging Details: Double food grade plastics inside; Environmental protection carton/barrel outside or Customized packages.
Delivery Time: 3-5 work days
Payment Terms: T/T, Western Union, MoneyGram
Supply Ability: Negotiation
Contact Now
Detailed Product Description
Synonyms: Evista ; Raloxifene Hydrochloride Formula: C28H28ClNO4S
Formula Weight: 510.044 G·mol−1 CAS: 82640-04-8
Color: Light Yellow Crystalline Powder Assay: 99% Min

Raloxifene HCl Evista Estrogen receptor antagonist CAS 82640-04-8


Product Name Raloxifene HCl
CAS No. 82640-04-8
Synonyms Evista; Raloxifene hydrochloride
Molecular Formula C28H28ClNO4S
Molecular Weight 510.044 g·mol−1
Structure 99% Min Assay Raloxifene HCL Evista Estrogen Receptor Antagonist CAS 82640-04-8
Purity 99% Min
Usage the second generation of estrogen receptor antagonist
Character Light yellow crystalline powder
Grade Pharmaceutical Grade
Standard USP,CP
Delivery method EMS, DHL, TNT, FedEx

Raloxifene hydrochloride is actually a second-generation Selective Estrogen Receptor Modulator (SERM) with the benzothiophene family. This drug is related in effect to tamoxifen, exhibiting estrogen receptor antagonist (blocking) properties in some tissues although acting as an estrogen receptor agonist (activator) in other folks.

The key point of variation between these two agents is their tissue selectivity. While raloxifene hydrochloride can be a powerful anti-estrogen in breast and uterine tissues, it seems to become estrogenic in bone. This permits it to defend bone density, mimicking the advantageous effects of endogenous estradiol.

In a role that was novel for an anti-estrogen, raloxifene hydrochloride was approved by the FDA for the prevention and remedy of osteoporosis in post-menopausal women. It is also being investigated for a number of other possible makes use of, such as the treatment and prevention of cardiovascular illness, breast cancer, gynecomastia, prostate cancer, acromegaly, and uterine cancer.


Evista (raloxifene hydrochloride) is definitely an estrogen agonist/antagonist, referred to as a selective estrogen receptor modulator (SERM) and belongs to the benzothiophene class of compounds. The biological actions of raloxifene are largely mediated through binding to estrogen receptors.

This binding outcomes in activation of estrogenic pathways in some tissues (agonism) and and the blockade of estrogenic pathways in other tissues (antagonism). The agonistic or antagonistic activity of raloxiffene depends upon the extent of recruitment of coactivators and corepressors to estrogen receptor (ER) target gene promotors.

Raloxifene appears to act as an estrogen agonist in bone. It decreases bone resorption and bone turnover, increases bone mineral density and decreases fracture incidence.
Raloxifene HCl Evista Estrogen receptor antagonist CAS 82640-04-8



Product Raloxifene HCl CAS No. 82640-04-8
Quantity 1KG Date Of Manu 2019-01-06
Test standard In-house quality standard Expiry date 2021-01-05
Items Specifications Results
Appearance Light yellow crystalline powder Light yellow crystalline powder
Assay ≥99% 99.39%
Loss on Drying ≤1.0% 0.4%
Conclusion: The product meets In-house specifications.

More information please contact us NOW!

Contact Details
Xi'an Oripharm Technology Co.,Ltd

Contact Person: forrest

Send your inquiry directly to us (0 / 3000)